<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antibodies against epidermal growth factor receptor (EGFR)--cetuximab and panitumumab--are widely used to treat <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Unfortunately, patients eventually develop resistance to these agents </plain></SENT>
<SENT sid="2" pm="."><plain>We describe an acquired EGFR ectodomain mutation (S492R) that prevents cetuximab binding and confers resistance to cetuximab </plain></SENT>
<SENT sid="3" pm="."><plain>Cells with this mutation, however, retain binding to and are growth inhibited by panitumumab </plain></SENT>
<SENT sid="4" pm="."><plain>Two of ten subjects studied here with disease progression after cetuximab treatment acquired this mutation </plain></SENT>
<SENT sid="5" pm="."><plain>A subject with cetuximab resistance harboring the S492R mutation responded to treatment with panitumumab </plain></SENT>
</text></document>